XTL Biopharmaceuticals Ltd. (XTLB) Earnings History
Annual and quarterly earnings data from 2003 to 2024
Loading earnings history...
XTLB EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
XTLB Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 0.7% | -481.6% | -227.7% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export XTLB earnings history in CSV or JSON format
Free sign-in required to download data
XTL Biopharmaceuticals Ltd. (XTLB) Earnings Overview
As of May 8, 2026, XTL Biopharmaceuticals Ltd. (XTLB) reported trailing twelve-month net income of -$1M. The company earned $-9.33 per diluted share over the past four quarters, with a net profit margin of -227.7%.
Looking at the long-term picture, XTLB's historical earnings data spans multiple years. The company achieved its highest annual net income of $3M in fiscal 2018.
XTL Biopharmaceuticals Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NRXP (-$38M net income, -2336.5% margin), SIGA (-$4.04T net income, 24.6% margin), BFRI (-$11M net income, -25.3% margin), XTLB has outperformed on profitability metrics. Compare XTLB vs NRXP →
XTLB Earnings vs Peers
Earnings metrics vs comparable public companies
XTLB Historical Earnings Data (2003–2024)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$1M | -57531.9% | -$2M | $-9.60 | -227.7% | -481.6% |
| 2023 | $-1,782 | +99.9% | $-765,000 | $0.00 | - | - |
| 2022 | -$1M | -409.9% | $-880,000 | $-16.00 | - | - |
| 2021 | $435,000 | +155.6% | -$1M | $4.48 | - | - |
| 2020 | $-782,000 | +41.9% | $-948,000 | $-36.48 | - | - |
| 2019 | -$1M | -145.1% | $-842,000 | $-16.64 | - | - |
| 2018 | $3M | +482.3% | $-793,000 | $37.12 | - | - |
| 2017 | $-781,000 | +69.3% | -$1M | $-10.88 | - | - |
| 2016 | -$3M | +41.0% | -$3M | $-59.52 | - | - |
| 2015 | -$4M | -70.6% | -$4M | $-104.32 | - | - |
See XTLB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XTLB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XTLB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXTLB — Frequently Asked Questions
Quick answers to the most common questions about buying XTLB stock.
Is XTLB growing earnings?
XTLB TTM EPS: $-9.33. Net income: $-1M. Earnings growth: N/A.
What are XTLB's profit margins?
XTL Biopharmaceuticals Ltd. net margin is -227.7%, with operating margin at -481.6%. Below-average margins reflect competitive or cost pressures.
How consistent are XTLB's earnings?
XTLB earnings data spans 2003-2024. The current earnings trend is N/A YoY. Historical data enables comparison across business cycles.